Acrivon Therapeutics (ACRV) Competitors $1.52 -0.03 (-1.94%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.51 -0.01 (-0.66%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. NVCT, MCRB, LFVN, KYTX, MEIP, BDTX, GLSI, MIST, ELDN, and MOLNShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Nuvectis Pharma (NVCT), Seres Therapeutics (MCRB), Lifevantage (LFVN), Kyverna Therapeutics (KYTX), MEI Pharma (MEIP), Black Diamond Therapeutics (BDTX), Greenwich LifeSciences (GLSI), Milestone Pharmaceuticals (MIST), Eledon Pharmaceuticals (ELDN), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors Nuvectis Pharma Seres Therapeutics Lifevantage Kyverna Therapeutics MEI Pharma Black Diamond Therapeutics Greenwich LifeSciences Milestone Pharmaceuticals Eledon Pharmaceuticals Molecular Partners Nuvectis Pharma (NASDAQ:NVCT) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation. Which has preferable valuation and earnings, NVCT or ACRV? Nuvectis Pharma is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$19M-$1.17-5.26Acrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.68 Do analysts recommend NVCT or ACRV? Nuvectis Pharma currently has a consensus price target of $15.33, indicating a potential upside of 148.92%. Acrivon Therapeutics has a consensus price target of $15.50, indicating a potential upside of 919.74%. Given Acrivon Therapeutics' higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, NVCT or ACRV? Nuvectis Pharma has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Do insiders and institutionals have more ownership in NVCT or ACRV? 96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 11.9% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is NVCT or ACRV more profitable? Acrivon Therapeutics' return on equity of -50.78% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -150.81% -94.84% Acrivon Therapeutics N/A -50.78%-46.08% Does the media refer more to NVCT or ACRV? In the previous week, Acrivon Therapeutics had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 2 mentions for Acrivon Therapeutics and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.91 beat Acrivon Therapeutics' score of 0.97 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Overall Sentiment Nuvectis Pharma Very Positive Acrivon Therapeutics Positive SummaryAcrivon Therapeutics beats Nuvectis Pharma on 8 of the 13 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.76M$2.59B$5.85B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-0.6823.8575.3425.98Price / SalesN/A529.66514.55181.19Price / CashN/A171.1637.5660.44Price / Book0.275.3712.156.29Net Income-$80.56M$32.95M$3.29B$271.07M7 Day Performance14.29%1.28%0.74%3.87%1 Month Performance16.03%6.09%4.82%4.88%1 Year Performance-82.94%-2.15%60.58%26.12% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics3.4754 of 5 stars$1.52-1.9%$15.50+919.7%-83.5%$48.76MN/A-0.6858Short Interest ↓Gap DownNVCTNuvectis Pharma3.481 of 5 stars$6.56+0.5%$15.33+133.7%-5.2%$167MN/A-5.618MCRBSeres Therapeutics3.2128 of 5 stars$18.94-0.3%$73.67+288.9%-17.1%$165.81M$126.32M-4.12330LFVNLifevantage3.9996 of 5 stars$13.10flat$30.50+132.8%+14.2%$164.90M$200.16M18.99260Positive NewsKYTXKyverna Therapeutics3.2118 of 5 stars$3.71+0.3%$16.60+347.4%-43.9%$160.44M$7.03M-1.0196Positive NewsMEIPMEI Pharma0.9724 of 5 stars$4.86-6.5%N/A+4.2%$159.59M$65.30M-1.02100Upcoming EarningsGap UpBDTXBlack Diamond Therapeutics3.5569 of 5 stars$2.75-3.5%$12.40+350.9%-44.4%$156.57MN/A11.9690Positive NewsGLSIGreenwich LifeSciences1.5455 of 5 stars$11.48+0.2%$42.00+265.9%-21.2%$156.48MN/A-8.443MISTMilestone Pharmaceuticals2.4565 of 5 stars$1.84+1.7%$5.00+171.7%+33.3%$156.39M$1M-2.1930News CoveragePositive NewsAnalyst ForecastELDNEledon Pharmaceuticals3.0102 of 5 stars$2.59+0.8%$10.00+286.1%-4.0%$155.09MN/A-2.2110News CoverageShort Interest ↓MOLNMolecular Partners2.4238 of 5 stars$3.83+6.3%$12.00+213.7%-33.4%$151.40M$5.65M-1.84180 Related Companies and Tools Related Companies Nuvectis Pharma Competitors Seres Therapeutics Competitors Lifevantage Competitors Kyverna Therapeutics Competitors MEI Pharma Competitors Black Diamond Therapeutics Competitors Greenwich LifeSciences Competitors Milestone Pharmaceuticals Competitors Eledon Pharmaceuticals Competitors Molecular Partners Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRV Stock Alerts